Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid LeukemiaNicholas J. Short, Farhad Ravandi, Roland B. Walter et al.|JAMA Oncology|2020Cited by 380
Randomized Trial of Ibrutinib Versus Ibrutinib Plus Rituximab (Ib+R) in Patients with Chronic Lymphocytic Leukemia (CLL)Jan A. Burger, Michael J. Keating, Mariela Sivina et al.|Blood|2017Cited by 15